Open therapeutic science, from target to a fundable plan.
I'm Ruth-Anne Pai, PhD — an immunologist, protein designer, and person living with eosinophilic esophagitis (EoE). In one week I built an end-to-end body of work: mining EoE omics to nominate targets, designing antigen-specific protein therapeutics with ESM-family and folding models, and packaging it all into reusable software, manuscripts, and a development plan. Everything here is open.
Where would you like to start?
The work spans data mining, protein design, software, and a full biotech plan. Pick the entry point that fits you — each card points to the pages built for you.
Tools that work for any disease
The Therapeutic Program Architect turns your community's disease into a full, human-in-the-loop drug program. And the EoE plan was written patient-voice-first.
- → Therapeutic Program Architect (disease-agnostic)
- → Patient-centered differentiation
pMHC-II design & effector-target binders
Read the methods and structures behind the antigen-specific tolerance work and the CCL26/POSTN binder designs.
- → Manuscripts (pMHC-II & CCL26/POSTN)
- → Epitope & design pipelines
Project Tolera — a roadmap to patients
The full package: platform thesis, market, competitive whitespace, regulatory path, budget, and milestones.
- → Project Tolera (business + scientific plan)
- → Scientific evidence
Reusable skills & pipelines
Eight open repositories — skills for target mining, epitope mapping, market analysis, peer review, and media.
Omics-mined targets, reproducibly
A ten-stage pipeline from public GEO/PRIDE/CELLxGENE data to a ranked, druggability-annotated target shortlist.
The one-week story
How a citizen-scientist took EoE from "here is a disease" to IND-ready design and a plan — all in public.
Three integrated streams
Targets from public omics
Transcriptomic, proteomic, and single-cell EoE datasets mined for dysregulated genes, pathways, and cell populations — surfacing high-evidence, low-competition targets like CCL26 and POSTN.
Antigen-specific therapeutics
A 9-construct pMHC-II tolerance panel across dairy, wheat, and soy triggers — folded, groove-validated, and formulated on a multivalent nanoparticle — plus CCL26/POSTN effector-target binders.
From design to fundable plan
A disease-agnostic drug-program pipeline, a patient-voice-first business and scientific plan, and open repositories anyone can pick up and run.
